scholarly journals TGF-β Inhibitor SB431542 Promotes the Differentiation of Induced Pluripotent Stem Cells and Embryonic Stem Cells into Mesenchymal-Like Cells

2018 ◽  
Vol 2018 ◽  
pp. 1-13 ◽  
Author(s):  
Alessander Leyendecker Junior

Due to their potential for tissue engineering applications and ability to modulate the immune system and reduce inflammation, mesenchymal stem cells (MSCs) have been explored as a promising option for the treatment of chronic diseases and injuries. However, there are problems associated with the use of this type of cell that limit their applications. Several studies have been exploring the possibility to produce mesenchymal stem cells from pluripotent stem cells (PSCs). The aim of these studies is to generate MSCs with advantageous characteristics of both PSCs and MSCs. However, there are still some questions concerning the characteristics of MSCs derived from the differentiation of PSCs that must be answered before they can be used to treat diseases and injuries. The objective of this study was, therefore, to determine if PSCs exposed to SB431542, a TGF-β inhibitor, are able to differentiate to MSCs, judging by morphology, expression of mesenchymal and pluripotent stem cell markers, expression of pluripotency-related genes, and ability to differentiate to osteocytes and adipocytes. The results obtained demonstrated that it is possible to induce the differentiation of both embryonic stem cells and induce pluripotent stem cells into cells with characteristics that highly resemble those from MSCs through the inhibition of the TGF-β pathway.

2021 ◽  
Vol 22 (9) ◽  
pp. 5011
Author(s):  
Daehwan Kim ◽  
Sangho Roh

Stem cell research is essential not only for the research and treatment of human diseases, but also for the genetic preservation and improvement of animals. Since embryonic stem cells (ESCs) were established in mice, substantial efforts have been made to establish true ESCs in many species. Although various culture conditions were used to establish ESCs in cattle, the capturing of true bovine ESCs (bESCs) has not been achieved. In this review, the difficulty of establishing bESCs with various culture conditions is described, and the characteristics of proprietary induced pluripotent stem cells and extended pluripotent stem cells are introduced. We conclude with a suggestion of a strategy for establishing true bESCs.


Stem Cells ◽  
2013 ◽  
Vol 31 (4) ◽  
pp. 682-692 ◽  
Author(s):  
Yun-Shen Chan ◽  
Jonathan Göke ◽  
Xinyi Lu ◽  
Nandini Venkatesan ◽  
Bo Feng ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Jitong Guo ◽  
Baojiang Wu ◽  
Shuyu Li ◽  
Siqin Bao ◽  
Lixia Zhao ◽  
...  

Blastocyst injection and morula aggregation are commonly used to evaluate stem cell pluripotency based on chimeric contribution of the stem cells. To assess the protocols for generating chimeras from stem cells, 8-cell mouse embryos were either injected or cocultured with mouse embryonic stem cells and induced pluripotent stem cells, respectively. Although a significantly higher chimera rate resulted from blastocyst injection, the highest germline contribution resulted from injection of 8-cell embryos with embryonic stem cells. The fully agouti colored chimeras were generated from both injection and coculture of 8-cell embryos with embryonic stem cells. Additionally, microsatellite DNA screening showed that the fully agouti colored chimeras were fully embryonic stem cell derived mice. Unlike embryonic stem cells, the mouse chimeras were only generated from injection of 8-cell embryos with induced pluripotent stem cells and none of these showed germline transmission. The results indicated that injection of 8-cell embryos is the most efficient method for assessing stem cell pluripotency and generating induced pluripotent stem cell chimeras, embryonic stem cell chimeras with germline transmission, and fully mouse embryonic stem cell derived mice.


Author(s):  
Idrus Alwi

Penelitian terapi sel punca di dunia telah berkembang dengan pesat dalam beberapa dasa warsa terakhir, khususnya pada penyakit jantung seperti infark miokard akut, penyakit jantung koroner tahap akhir (PJTA) dan kardiomiopati. Di masa mendatang terapi sel punca dianggap sebagai batas akhir (final frontier) pengobatan berbagai penyakit. Oleh karena itu pengembangan terapi sel punca diharapkan dapat menjawab berbagai tantangan dalam tatalaksana berbagai penyakit secara mendasar. Indonesia merupakan salah satu pelopor terapi sel punca pada infark miokard akut di Asia Tenggara dan merupakan salah satu negara pertama di Asia selain Hongkong yang menggunakan alat NOGA untuk pemetaan (mapping) dan injeksi sel punca pada otot jantung melalui kateterisasi pada PJTA. Sel punca termasuk embryonic stem cells (ESC), cardiac stem cells (CSCs) dan induced pluripotent stem cells (iPSs) dapat mengalami diferensiasi menjadi kardiomiosit dan dapat mengembalikan fungsi kontraksi jantung. Sel tersebut juga dapat berdiferensiasi menjadi sel endotel, memicu pembentukan pembuluh darah baru (angiogenesis), mengembalikan sebagian sel otot jantung yang rusak menjadi tetap hidup, dan menghambat perluasan jaringan parut. Mekanisme lain terapi sel punca pada jantung yang saat ini banyak dianut adalah melalui efek parakrin. Terdapat beberapa metoda pemberian sel punca pada jantung yaitu intrakoroner, epikardial dan intravena. Penelitian di bidang kedokteran kardiovaskular regeneratif mengenai terapi sel punca akan terus berkembang di masa depan, termasuk mengenai jenis sel dan teknik terbaik pemberian sel punca.  


2009 ◽  
Vol 1 (1) ◽  
pp. 76-82 ◽  
Author(s):  
Mark Denham ◽  
Jessie Leung ◽  
Cheryl Tay ◽  
Raymond C.B. Wong ◽  
Peter Donovan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document